Magvanjav, Oyunbileg <br/><br/>
Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.  [electronic resource] 

 -  Journal of the American Heart Association  Nov 2017 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2047-9980 
<br/><br/><label>Standard No.: </label>10.1161/JAHA.117.006522  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adrenergic beta-Antagonists--adverse effects<br/>Adult<br/>Aged<br/>Aldehyde Dehydrogenase 1 Family<br/>Angiotensin-Converting Enzyme Inhibitors--therapeutic use<br/>Antihypertensive Agents--adverse effects<br/>Atenolol--adverse effects<br/>Blood Pressure--drug effects<br/>Calcium Channel Blockers--therapeutic use<br/>Chi-Square Distribution<br/>Drug Combinations<br/>Drug Resistance--genetics<br/>Female<br/>Florida<br/>Genome-Wide Association Study<br/>Georgia<br/>Humans<br/>Hydrochlorothiazide--adverse effects<br/>Hypertension--diagnosis<br/>Indoles--therapeutic use<br/>Logistic Models<br/>Male<br/>Middle Aged<br/>Multivariate Analysis<br/>Odds Ratio<br/>Pharmacogenetics<br/>Pharmacogenomic Variants<br/>Polymorphism, Single Nucleotide<br/>Prospective Studies<br/>Retinal Dehydrogenase--genetics<br/>Risk Factors<br/>Sodium Chloride Symporter Inhibitors--adverse effects<br/>Treatment Outcome<br/>Vasodilator Agents--therapeutic use<br/>Verapamil--therapeutic use<br/>Young Adult